Michael P Bogenschutz

Jan 20, 2025 | cancernetwork.com | Michael P Bogenschutz

Michael P. Bogenschutz, MD, director of the NYU Langone Center for Psychedelic Medicine and professor of Psychiatry at NYU Grossman School of Medicine, discussed insights related to the efficacy, implementation, and safety profile of psilocybin-assisted psychotherapy (PAP) in patients recently diagnosed with cancer.

Jan 20, 2025 | cancernetwork.com | Michael P Bogenschutz

CancerNetwork® spoke with Michael P. Bogenschutz, MD, director of the NYU Langone Center for Psychedelic Medicine and professor of Psychiatry at NYU Grossman School of Medicine, about psilocybin-assisted psychotherapy (PAP) in managing psychological challenges associated with serious cancer diagnoses following the publication of a pooled analysis of 2 phase 2 trials assessing the regimen in this patient population.

Jan 10, 2025 | cancernetwork.com | Michael P Bogenschutz

The main potential adverse effects (AEs) associated with psilocybin use include its acute mind-altering effects, which generally wear off after 6 hours following drug administration, according to Michael P. Bogenschutz, MD.

Jan 9, 2025 | cancernetwork.com | Michael P Bogenschutz

A need to provide effective medication to aid patients with psychological challenges related to a serious cancer diagnosis may be addressed by psilocybin, according to Michael P. Bogenschutz, MD.

Oct 7, 2024 | nature.com | Jennifer Mitchell |Michael P Bogenschutz |Michael C Mithoefer

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02565-4, published online 14 September 2023. In the version of the article initially published, some members of the MAPP2 Study Collaborator Group were listed only in the Supplementary Information.